A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Adocia
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- AUCGIR 0-6h
Study Overview
Brief Summary
This is a randomised, double-blind, three-period crossover euglycaemic clamp trial comparing pharmacokinetics and pharmacodynamics of BC Combo THDB0207 and Lantus® and Humalog® in subjects with type 1 diabetes.
Each subject will be randomly allocated to one of the 6 treatment sequences and will be administered single subcutaneous doses of BC Combo THDB0207, Lantus®, and Humalog® at three separate dosing visits.
Subjects will come in a fasted state to the clinical trial centre in the morning of each dosing day and stay at the clinical trial centre until the 24-hour clamp procedures have been terminated. Patients will return to the clinical trial centre for outpatient blood sampling visits for analysis of BC449 excipient until 144 hours after each dosing.
Detailed Description
Subjects will attend the study site in the morning in a fasted state and will be connected to an automated glucose clamp device (ClampArt). Prior to dose administration plasma glucose will be stabilised at a target level of 100 mg/dL by means of an intravenous infusion of glucose or insulin. IMP administration will be done by an unblinded person by means of subcutaneous injections in the abdominal wall.
Following each dosing a euglycaemic glucose clamp procedure will be carried out for up to 24 hours.
The pharmacodynamic assessment will be based on the time course of glucose infusion rate (GIR) and plasma glucose.
Plasma insulin concentrations will be measured using a specific validated bioanalytical method differentiating concentrations of insulin glargine, of its main metabolites insulin glargine-M1 and insulin glargine-M2, and of insulin lispro. Pharmacokinetic assessments will be based on total insulin (INS) concentration (insulin glargine + insulin glargine-M1 + insulin glargine-M2 + insulin lispro).
The investigation of PK properties of the BC449 excipient after dosing with BC Combo THDB0207 will be based on blood samples collected during the clamp procedure and at daily outpatient visits until 144 hours after dose administration.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 64 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Type 1 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
- •HbA1c ≤8.5%
- •Total insulin dose of < 1.2 U/kg/day
- •BMI between 20.0 and 29.9 kg/m2 (both inclusive)
- •Treated with insulin regimen for ≥ 12 months prior to screening
- •Using multiple dosing insulin therapy (MDI) with basal and bolus insulin or insulin pump therapy (continuous subcutaneous insulin infusion, CSII)
- •Fasting C-peptide <= 0.30 nmol/L
Exclusion Criteria
- •Known or suspected hypersensitivity to the IMPs or any of the excipients or to any component of the IMP formulation.
- •Type 2 diabetes mellitus
- •Use of oral antidiabetic drugs (OADs) and/or GLP-1 receptor agonists (e.g. exenatide, liraglutide)
- •Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial
- •Clinically significant abnormal screening laboratory tests, as judged by the Investigator considering the underlying disease
- •Clinically relevant comorbidity, capable of constituting a risk for the subject when participating in the trial or of interfering with the interpretation of data
- •Systolic blood pressure < 90 mmHg or >139 mmHg and/or diastolic blood pressure < 50 mmHg or > 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension)
- •Heart rate at rest outside the range of 50-90 beats per minute.
- •More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months or hypoglycaemia unawareness as judged by the investigator
- •Women of childbearing potential who are not using a highly effective contraceptive method.
Arms & Interventions
BC Combo THDB0207
Single administration of BC Combo THDB0207
Intervention: Euglycemic clamp with BC Combo THDB0207 (Drug)
Lantus®
Single administration of Lantus®
Intervention: Euglycemic clamp with Lantus® (Drug)
Humalog®
Single administration of Humalog®
Intervention: Euglycemic clamp with Humalog® (Drug)
Outcomes
Primary Outcomes
AUCGIR 0-6h
Time Frame: From t=0 to t=6 hours after IMP administration
Area under the glucose infusion rate curve until 6 hours after dosing of BC Combo THDB0207 and Lantus®
AUCGIR 6-24h
Time Frame: From t=6 to t=24 hours after IMP administration
Area under the glucose infusion rate curve from 6 hours to 24 hours after dosing of BC Combo THDB0207 and Humalog®
Secondary Outcomes
- AUCINS 0-4h(From t=0 to t=4 hours after IMP administration)
- RBA(From t=0 to t=24 hours after IMP administration)
- Local tolerability(From the first IMP administration to the follow-up visit (i.e. up to 11 weeks))
- AUCGIR 0-last(From t=0 to t=24 hours after IMP administration)
- AUCGIR 0-4h(From t=0 to t=4 hours after IMP administration)
- GIRmax(From t=0 to t=24 hours)
- AUCINS 0-24h(From t=0 to t=24 hours after IMP administration)
- tGIRmax(From t=0 to t=24 hours)
- tonset of action(From t=0 to t=24 hours after IMP administration)
- AUCINS 6-24h(From t=6 to t=24 hours after IMP administration)
- AUCINS 4-12h(From t=4 to t=12 hours after IMP administration)
- AUCINS 0-6h(From t=0 to t=6 hours after IMP administration)
- AUCINSlast(From t=0 to t=24 hours)
- Cmax INS(From t=0 to t=24 hours after IMP administration)
- AUCBC 0-12h(From t=0 to t=12 hours after IMP administration)
- AUCBC 0-24h(From t=0 to t=24 hours after IMP administration)
- AUCBC 0-last(From t=0 to t=144 hours after IMP administration)
- Adverse Events(From the first IMP administration to the follow-up visit (i.e. up to 11 weeks))